Recovering scientist turned early stage VC A biotech optimist fighting gravity

The Incredible Expanding Universe of Biotech Stocks
September 21, 2018

The biotech sector is unique relative to the rest of the stock market in many ways, but one that is often overlooked: its expansionary public equity market footprint. It’s been well appreciated by market analysts that the universe of U.S.

Leave a comment

Biotech Venture Deal Terms Are More “Startup-Friendly” Than Ever
September 10, 2018

Biotech is booming, with eye-popping new financings seemingly announced daily. The sector is having an epic year for startup fundraising, breaking records for what will end up as the most active private biotech financing year ever. Although overall sentiment in

Leave a comment

IPO: A Go-Go Or A No-No?
September 4, 2018

This blog was written by Jeb Keiper, CFO & CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Elon Musk has a flare for the dramatic, shocking Wall Street (and others) the first week

Leave a comment

Hard Core Values
August 9, 2018

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. Early in the morning of April 24, 2018, I woke with a knot in my stomach because I knew

Leave a comment

Hotspot Therapeutics Turns Up The Heat On Natural Allostery
July 17, 2018

Most conventional small molecule drugs engage directly with the engine of a protein’s function, aiming to often turning off an enzymatic activity associated with a disease. These drugs bind and compete against the natural substrate of the protein at what

Leave a comment

A Hat Trick Of Cell And Gene Therapy IPOs: Avro, Magenta, and Unum
June 28, 2018

Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Less than three months earlier, Unum Therapeutics priced its IPO. All three biotech companies are emerging leaders in the cell and gene therapy space, broadly defined. They

Leave a comment

Float Like A Butterfly: Agility In Biotech
June 13, 2018

This blog was written by Jonathan Montagu, CEO and co-founder of Hotspot Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around

Leave a comment

Farewell to Zafgen: A Personal Reflection On Board Evolution
June 7, 2018

Today, Zafgen announced my resignation from their Board of Directors after 12 years of service. It’s a bittersweet moment for me: having been there since the beginning, I’ve watched, and supported, the Zafgen story through all the ups and downs

Leave a comment

Biotech CEO Pay: Inflation Held At Bay
June 1, 2018

The private biotech sector is awash in capital today: funding over the last few quarters has been record-breaking, up over 250% since 2013, as biotech CEOs have worked hard to strengthen their companies’ balance sheets.  But in the process of

Leave a comment

Trains, Bicycles, And Business Development
May 30, 2018

This blog post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. It’s heresy to write this but it’s trains not bicycles that come to mind when describing our partnering

Leave a comment

New Directions In Alzheimer’s Disease Research And Development
May 15, 2018

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. Disappointing results in Alzheimer’s clinical trials seem to be announced on an almost monthly, and sometimes weekly basis: Merck’s

Leave a comment

Right From The Beginning: Returning To The Origins Of The Orphan Drug Movement
May 1, 2018

This blog was co-written by Doug Kerr, Head of Preclinical Research & Clinical Development, and Geoff McDonough, CEO, both of GenerationBio, as part of the From The Trenches feature of LifeSciVC. Our industry stands at the beginning of the most

Leave a comment